Evaluation of Nanoparticle Uptake in Co-culture Cancer Models

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Costa, Elisabete C ^a   Gaspar, Vítor M ^a   Marques, João G ^a   Coutinho, Paula ^a,b   Correia, Ilídio J ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Unidade de Investigação para o Desenvolvimento do Interior do IPG UDI IPG   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHITOSAN; HISTIDINE; NANOCARRIER; NANOPARTICLE; PLASMID DNA;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL NUCLEUS; CELL POPULATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; SURFACE PROPERTY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FIBROBLASTS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84880827252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070072     Document Type: Article

References (58)

1. Wagner V, Dullaart A, Bock AK, Zweck A, (2006) The emerging nanomedicine landscape. Nature biotechnology 24: 1211-1218.
2. Allen TM, (2002) Ligand-targeted therapeutics in anticancer therapy. Nature Reviews Cancer 2: 750-763.
3. Parveen S, Misra R, Sahoo SK, (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8: 147-166.
4. Yih T, Al-Fandi M, (2006) Engineered nanoparticles as precise drug delivery systems. Journal of cellular biochemistry 97: 1184-1190.
5. Nagpal K, Singh SK, Mishra DN, (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chemical and Pharmaceutical Bulletin 58: 1423-1430.
6. Sinha R, Kim GJ, Nie S, Shin DM, (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics 5: 1909-1917.
7. Shi J, Votruba AR, Farokhzad OC, Langer R, (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano letters 10: 3223-3230.
8. Moses MA, Brem H, Langer R, (2003) Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4: 337-341.
9. Stammati AP, Silano V, Zucco F, (1981) Toxicology investigations with cell culture systems. Toxicology 20: 91-153.
10. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, et al. (2006) Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicological Sciences 90: 23-32.
11. HogenEsch H, Nikitin AY, (2012) Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models. Journal of Controlled Release 164: 183-186.
12. Duell BL, Cripps AW, Schembri MA, Ulett GC, (2011) Epithelial cell coculture models for studying infectious diseases: benefits and limitations. Journal of Biomedicine and Biotechnology 2011: 1-9.
13. Miki Y, Ono K, Hata S, Suzuki T, Kumamoto H, et al. (2012) The advantages of co-culture over mono cell culture in simulating in vivo environment. The Journal of Steroid Biochemistry and Molecular Biology 131: 68-75.
14. Tumarkin E, Tzadu L, Csaszar E, Seo M, Zhang H, et al. (2011) High-throughput combinatorial cell co-culture using microfluidics. Integrative Biology 3: 653-662.
15. Purpura KA, Bratt-Leal AM, Hammersmith KA, McDevitt TC, Zandstra PW, (2011) Systematic engineering of 3D pluripotent stem cell niches to guide blood development. Biomaterials 33: 1271-1280.
16. Streuli CH, Bailey N, Bissell MJ, (1991) Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. The Journal of Cell Biology 115: 1383-1395.
17. Krause S, Maffini MV, Soto AM, Sonnenschein C, (2010) The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC cancer 10: 263.
18. Burguera EF, Bitar M, Bruinink A, (2010) Novel in vitro co-culture methodology to investigate heterotypic cell-cell interactions. European Cells and Materials 19: 166-179.
19. Le Droumaguet B, Nicolas J, Brambilla D, Mura S, Maksimenko A, et al. (2012) Versatile and Efficient Targeting Using a Single Nanoparticulate Platform: Application to Cancer and Alzheimer's Disease. ACS nano 6: 5866-5879.
20. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E, (2012) European cancer mortality predictions for the year 2012. Annals of oncology 23: 1044-1052.
21. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians 63: 11-30.
22. Feinberg AP, Ohlsson R, Henikoff S, (2006) The epigenetic progenitor origin of human cancer. Nature reviews genetics 7: 21-33.
23. Ben-Baruch A, (2002) Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression-reciprocal tumor-microenvironment interactions. Breast Cancer Research 5: 31-36.
24. Liotta LA, Kohn EC, (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
25. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504.
26. Cirri P, Chiarugi P, (2012) Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer and Metastasis Reviews 31: 195-208.
27. Strell C, Rundqvist H, Östman A, (2012) Fibroblasts-a key host cell type in tumor initiation, progression, and metastasis. Upsala journal of medical sciences 117: 187-195.
28. Lu P, Weaver VM, Werb Z, (2012) The extracellular matrix: A dynamic niche in cancer progression. The Journal of Cell Biology 196: 395-406.
29. Bhowmick NA, Neilson EG, Moses HL, (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
30. Loeffler M, Kruger J, Niethammer AG, Reisfeld RA, (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. Journal of Clinical Investigation 116: 1955-1962.
31. Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg A, Flomenberg N, et al. (2011) Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 10: 2521-2528.
32. Östman A, (2012) The tumor microenvironment controls drug sensitivity. Nature Medicine 18: 1332-1334.
33. Mitra S, Stemke-Hale K, Mills GB, Claerhout S, (2012) Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy. Cancer science 103: 400-407.
34. Liu L, Bai Y, Song C, Zhu D, Song L, et al. (2010) The impact of arginine-modified chitosan-DNA nanoparticles on the function of macrophages. Journal of Nanoparticle Research 12: 1637-1644.
35. Gaspar VM, Marques JG, Sousa F, Louro RO, Queiroz JA, et al. (2013) Biofunctionalized nanoparticles with pH-responsive and cell penetrating blocks for gene delivery. Nanotechnology 24: Article in press. doi: 10.1088/0957-4484/1024/1027/275101.
36. Moreira C, Oliveira H, Pires L, Simões S, Barbosa M, et al. (2009) Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomaterialia 5: 2995-3006.
37. Gaspar VM, Correia IJ, Sousa Â, Silva F, Paquete CM, et al. (2011) Nanoparticle mediated delivery of pure P53 supercoiled plasmid DNA for gene therapy. Journal of Controlled Release 156: 212-222.
38. Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, et al. (2010) Receptor-mediated gene delivery using pamam dendrimers conjugated with peptides recognized by mesenchymal stem cells. Molecular Pharmaceutics 7: 763-774.
39. Heneweer M, Muusse M, Dingemans M, De Jong PC, Van Den Berg M, et al. (2005) Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicological Sciences 83: 257-263.
40. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, et al. (2010) Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9: 2423-2433.
41. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, et al. (2012) Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. Cancer Biology & Therapy 12: 1085-1097.
42. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, et al. (2011) Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell cycle 10: 1772-1783.
43. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW, (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70: 537-546.
44. Iamazaki ET, de Britto D, Schmitt CC, Campana Filho SP, Neumann MG, (2004) Preparation of substituted ionic carbohydrate polymers and their interactions with ionic surfactants. Colloid and Polymer Science 283: 33-40.
45. Luo K, Li C, Li L, She W, Wang G, et al. (2012) Arginine functionalized peptide dendrimers as potential gene delivery vehicles. Biomaterials 33: 4917-4927.
46. Cho K, Wang X, Nie S, Shin DM, (2008) Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research 14: 1310-1316.
47. Polyak K, Haviv I, Campbell IG, (2009) Co-evolution of tumor cells and their microenvironment. Trends in Genetics 25: 30-38.
48. Soule H, Vazquez J, Long A, Albert S, Brennan M, (1973) A human cell line from a pleural effusion derived from a breast carcinoma. Journal of the National Cancer Institute 51: 1409-1416.
49. Engel LW, Young NA, (1978) Human breast carcinoma cells in continuous culture: a review. Cancer research 38: 4327-4339.
50. Baskin L, Macarak E, Duckett J, Snyder H, Howard P, (1993) Culture of urethral fibroblasts: cell morphology, proliferation and extracellular matrix synthesis. Journal of Urology 150: 1260-1260.
51. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, et al. (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clinical Cancer Research 14: 370-378.
52. Knazek RA, Lippman ME, Chopra HC, (1977) Formation of solid human mammary carcinoma in vitro. Journal of the National Cancer Institute 58: 419-422.
53. Weigelt B, Bissell MJ, (2008) Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Seminars in cancer biology 18: 311-321.
54. Bissell MJ, (2007) Modelling molecular mechanisms of breast cancer and invasion: lessons from the normal gland. Biochemical Society transactions 35: 18-22.
55. Borchard G, (2001) Chitosans for gene delivery. Advanced drug delivery reviews 52: 145-150.
56. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S, (2012) Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. Journal of Controlled Release 159: 181-188.
57. Wu H, Zhu L, Torchilin VP, (2012) pH-sensitive poly (histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 34: 1213-1222.
58. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, et al. (2002) Possible existence of common internalization mechanisms among arginine-rich peptides. Journal of Biological Chemistry 277: 2437-2443.